BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for PR Young

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.EBI
Amri
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.EBI
Abbott Laboratories
 
Structural analysis of 2-aryl-1,3-dione compounds as inhibitors of 5-lipoxygenaseEBI
TBA
5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.EBI
Abbott Laboratories
In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.EBI
Abbott Laboratories
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.EBI
Zenith Epigenetics
Orally active hydroxamic acid inhibitors of leukotriene biosynthesis.EBI
Abbott Laboratories
Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis.EBI
Abbott Laboratories
BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTIONBDB
Reviral
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereofBDB
Albany Molecular Research
Compound as WNT signaling inhibitor, composition, and use thereofBDB
Curegenix